X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pluristyx will be supporting a collaboration between Kiadis Pharma and the Advanced Regenerative Manufacturing Institute’s BioFabUSA program working on Kiadis’ COVID-19 research and development program K-NK-ID101 as a universal countermeasure to fight COVID-19.
Lead Product(s): K-NK-ID101
Therapeutic Area: Infections and Infectious Diseases Product Name: K-NK-ID101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 12, 2020
Details:
The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.
Lead Product(s): ESI human embryonic stem cells
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AgeX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
